These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32901873)

  • 1. iTRAQ‑based proteomic analysis reveals potential regulatory networks in dust mite‑related asthma treated with subcutaneous allergen immunotherapy.
    Bai J; Zhong JY; Liao W; Hu R; Chen L; Wu XJ; Liu SP
    Mol Med Rep; 2020 Nov; 22(5):3607-3620. PubMed ID: 32901873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects.
    Chaoul N; Albanesi M; Giliberti L; Rossi MP; Nettis E; Di Bona D; Caiaffa MF; Macchia L
    Int Arch Allergy Immunol; 2019; 179(1):37-42. PubMed ID: 30921804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
    Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
    Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite].
    Li L; Hui Y; Qian J; Guo Y; Zhang XL; Zhang XJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 May; 15(5):368-71. PubMed ID: 23676940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children.
    Rosewich M; Arendt S; El Moussaoui S; Schulze J; Schubert R; Zielen S
    Pediatr Allergy Immunol; 2013 Aug; 24(5):434-40. PubMed ID: 23578317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of dust mite subcutaneous immunotherapy in children with allergic asthma： a prospective randomized controlled study].
    Wang YN; Lu SQ; Chen H; Li YQ; Lu HY; Zhu H; Chang M
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Jun; 26(6):559-566. PubMed ID: 38926371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the effect of early subcutaneous specific immunotherapy on the levels of dust mite allergen-specific antibodies and polyunsaturated fatty acid metabolism].
    Li SY; Zheng PY; Zhai YY; Zhang YD; Gan H; Huang HM; Luo WT; Jiang MY; Zhang GZ; Zhong RF; Cheng ZK; Sun SX; Sun BQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):778-790. PubMed ID: 38955724
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
    Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
    Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
    Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
    J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.
    Nahm DH; Kim ME; Kwon B; Cho SM; Ahn A
    Yonsei Med J; 2016 Nov; 57(6):1420-6. PubMed ID: 27593870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis].
    Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.